# Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors

> **NCT01215864** · PHASE1 · COMPLETED · sponsor: **Traslational Cancer Drugs Pharma, SL** · enrollment: 28 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TCD-717

## Key facts

- **NCT ID:** NCT01215864
- **Lead sponsor:** Traslational Cancer Drugs Pharma, SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215864, "Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01215864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*